Bringing the fundamentals into focus…
Back to 4D Molecular Therapeutics, Inc.
How 4D Molecular Therapeutics, Inc. stacks up
FDMT · against 485 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #316 of 486 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score171 peers with a valuation score of 0–9, including FDMT · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -60.3% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -27.2% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -23.6% vs peer median 0.0%
Metric by metric
Position: dot = FDMT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | FDMT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 475 reported | -22.0% | 0.6% | 10% | 30% | |
| EBITDA yieldHigher is better · 490 reported | -55.9% | 3.6% | 3% | 50% | |
| Free cash flow yieldHigher is better · 202 reported | -23.6% | -4.2% | 9% | 20% | |
| Book yieldHigher is better · 484 reported | 61.8% | 45.4% | 66% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around FDMT| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 316 | 455M USD | 8 | 36 | |
| 316 | 486M USD | 8 | 16 | |
| 316 | 551M USD | 8 | 27 | |
| 316 | 508M EUR (≈$559M) | 8 | 21 | |
| 316 | 660M USD | 8 | 43 | |
| 316 | 375M USD | 8 | 46 | |
| 316 | 533M USD | 8 | 36 | |
| 316 | 598M USD | 8 | 49 | |
| 316 | 888M USD | 8 | 25 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score